Claim OwnershipAvalere Essential Voice
Subscribed: 4Played: 110
Subscribe
© 2020
Description
Twenty years ago, Avalere set out to be the essential voice in improving healthcare. Rest your eyes or use your commute time to listen to our experts discuss the hot topics that you need to track.
93 Episodes
Reverse
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.
Tune into the second episode in our miniseries focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.
Tune into the third episode in the Avalere Health Essential Voice podcast series focused on Agency decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs) by considering how potential policy and market catalysts 3 to 5 years out may help stakeholders think through opportunities and risks at key decision points ranging from early in development to implications for Part D.
Tune into the second episode in the Avalere Health Essential Voice podcast series focused on the how CMS and Medicare coverage decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs)that have coverage with evidence development (CED) requirements, how FDA and CMS’s evidence questions can be complimentary, and the ways in which manufacturer evidence generation plans can address those goals, using the NCD on monoclonal antibodies for Alzheimer's disease as an example.
Tune into the first episode in the Avalere Health Essential Voice podcast series focused on how CMS and Medicare coverage decisions define patient access. In this segment, our Market Access experts discuss national coverage determinations (NCDs), specifically those with coverage with evidence development (CED), their impacts to patient access, and considerations for life sciences companies.
In the third and final episode of the Avalere Health Essential Voice miniseries focused on kidney care, our experts share insights on disparities in kidney care. Listen to previous episodes in this series: Exploring the Kidney Care Environment: Key Players, Treatment, and Payment Systems Exploring the Kidney Care Environment, Part II, Policy and Payment Trends
In the second episode of the Avalere Health Essential Voice miniseries focused on kidney care, our experts share their perspective on policy and payment trends. Listen to previous episodes in this series: Exploring the Kidney Care Environment: Key Players, Treatment, and Payment Systems
In this episode of Avalere Health Essential Voice, we kick off our miniseries focused on the evolving kidney care landscape.
In this episode of the Avalere Health Essential Voice, we welcome leaders from the National Alliance of State & Territorial AIDS Directors (NASTAD) to discuss state HIV policies and barriers to ending the HIV epidemic in the US.
In this episode of the Avalere Health Essential Voice, we welcome Carl Schmid, Executive Director at the HIV + Hepatitis Policy Institute, to commemorate World AIDS Day on December 1.
In this episode of Avalere Health Essential Voice, our experts continue their discussion on channel strategy development for bringing a drug to market. Tune into Part 1 here: https://avalere.com/podcasts/navigating-distribution-and-third-party-logistics-part-i Tune into Part 2 here: https://avalere.com/podcasts/navigating-distribution-and-third-party-logistics-part-ii
In this episode of Avalere Health Essential Voice, our experts welcome leaders from Gilead Sciences and Jazz Pharmaceuticals to discuss channel distribution strategy. Tune into Part 1 here: https://avalere.com/podcasts/navigating-distribution-and-third-party-logistics-part-i
In this episode of Avalere Health Essential Voice, the fifth and final in our Medicare Part D miniseries, our experts discuss the Center for Medicare & Medicaid Innovation (CMMI) and where we can anticipate some activity in the coming year, particularly as it relates to the Part D program.
In this episode of Avalere Health Essential Voice, the fourth in our Medicare Part D miniseries, our experts discuss key elements of the legislative process including budget neutrality and congressional scoring.
In this episode of Avalere Health Essential Voice, the third in our Medicare Part D miniseries, our experts discuss policy changes and the impact on market access.
In this episode of Avalere Health Essential Voice, the second in our Medicare Part D miniseries, our experts discuss how health plans make decisions within Part D.
In this episode of the Avalere Health Essential Voice Disease Education series, our experts discuss the need for patient support in cell and gene therapies and the ways in which various stakeholders provide it.
In this episode of Avalere Health Essential Voice, the first in our Medicare Part D miniseries, our experts discuss Part D trends and pressures in the evolving drug pricing environment.
Comments
Download from Google Play
Download from App Store
United States